stockrow
Saturday 7 November 2026
Export SNDX’s income statement to Excel — free account
Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.
- Revenue
- +81.6%
- EPS
- +21.4%
- Free cash flow
- +61.4%
- Total debt
- +71.1%
Quarter to September 2026, against a year earlier
9.54
0.17
+1.81%
Follow SNDX
Alert me
Syndax Pharmaceuticals, Inc. (SNDX) P/E ratio
Syndax Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 155× (September 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2021 | 50.9× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 155×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.4× |
| MGTX MeiraGTx Holdings PLC compare | 11.8× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 34.2× |
| LTGO Latigo Biotherapeutics Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)